1. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
- Author
-
Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T, DELOS Study Group, POLITANO, Luisa, Lutz, S (Beitragende*r), Buyse, Gm, Voit, T, Schara, U, Straathof, C, D'Angelo, Mg, Bernert, G, Cuisset, Jm, Finkel, R, Goemans, N, Mcdonald, Cm, Rummey, C, Meier, T, Politano, Luisa, and DELOS Study, Group
- Subjects
Male ,medicine.medical_specialty ,Pediatrics ,Adolescent ,Ubiquinone ,Duchenne muscular dystrophy ,Population ,Medizin ,Peak Expiratory Flow Rate ,Placebo ,Antioxidants ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Clinical endpoint ,Humans ,Medicine ,Idebenone ,Respiratory function ,Child ,education ,030304 developmental biology ,Medicine(all) ,0303 health sciences ,education.field_of_study ,Intention-to-treat analysis ,business.industry ,General Medicine ,Respiration Disorders ,medicine.disease ,Respiratory Muscles ,Respiratory Function Tests ,3. Good health ,Muscular Dystrophy, Duchenne ,Treatment Outcome ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
SummaryBackgroundCardiorespiratory failure is the leading cause of death in Duchenne muscular dystrophy. Based on preclinical and phase 2 evidence, we assessed the efficacy and safety of idebenone in young patients with Duchenne muscular dystrophy who were not taking concomitant glucocorticoids.MethodsIn a multicentre phase 3 trial in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy, Spain, and the USA, patients (age 10–18 years old) with Duchenne muscular dystrophy were randomly assigned in a one-to-one ratio with a central interactive web response system with a permuted block design with four patients per block to receive idebenone (300 mg three times a day) or matching placebo orally for 52 weeks. Study personnel and patients were masked to treatment assignment. The primary endpoint was change in peak expiratory flow (PEF) as percentage predicted (PEF%p) from baseline to week 52, measured with spirometry. Analysis was by intention to treat (ITT) and a modified ITT (mITT), which was prospectively defined to exclude patients with at least 20% difference in the yearly change in PEF%p, measured with hospital-based and weekly home-based spirometry. This study is registered with ClinicalTrials.gov, number NCT01027884.Findings31 patients in the idebenone group and 33 in the placebo group comprised the ITT population, and 30 and 27 comprised the mITT population. Idebenone significantly attenuated the fall in PEF%p from baseline to week 52 in the mITT (−3·05%p [95% CI −7·08 to 0·97], p=0·134, vs placebo −9·01%p [–13·18 to −4·84], p=0·0001; difference 5·96%p [0·16 to 11·76], p=0·044) and ITT populations (−2·57%p [–6·68 to 1·54], p=0·215, vs −8·84%p [–12·73 to −4·95], p
- Published
- 2015